Effect of acid suppressant medications on the laxative action of magnesium preparations in patients with opioid-induced constipation : A pharmacovigilance analysis of the FDA Adverse Event Reporting System
Objective: Magnesium oxide is widely used for treating opioid-induced constipation, a serious analgesic-associated problem. Opioid analgesic users are often prescribed non-steroidal anti-inflammatory drugs, which are sometimes combined with acid suppressants to prevent gastrointestinal adverse events. Magnesium preparations combined with acid suppressants may diminish magnesium preparations' laxative effect. This study was aimed at evaluating the effect of magnesium preparations combined with acid suppressants on the incidence of opioid-induced constipation by using the Food and Drug Administration Adverse Event Reporting System. Methods: Adverse events were defined per the Medical Dictionary for Regulatory Activities; the term 'constipation (preferred term code: 10010774)' was used for analysis. After adjusting for patient background factors using propensity score matching, acid suppressants' effect on constipation incidence was evaluated in opioid users prescribed magnesium preparations alone as laxatives by using a test for independence. Key Findings: The Food and Drug Administration Adverse Event Reporting System contains 14,475,614 reports for January 2004 to December 2021. Significantly increased constipation incidence was related to magnesium preparations combined with acid suppressants, especially proton pump inhibitors (P < 0.0001, McNemar's test). Conclusion: Magnesium preparations combined with acid suppressants may diminish magnesium preparations' laxative effect; healthcare professionals should pay attention to this issue.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Die Pharmazie - 78(2023), 11 vom: 04. Dez., Seite 245-250 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maezawa, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Analgesics, Opioid |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 08.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1691/ph.2023.3624 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36668891X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36668891X | ||
| 003 | DE-627 | ||
| 005 | 20240114232145.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1691/ph.2023.3624 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1252.xml |
| 035 | |a (DE-627)NLM36668891X | ||
| 035 | |a (NLM)38178284 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maezawa, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of acid suppressant medications on the laxative action of magnesium preparations in patients with opioid-induced constipation |b A pharmacovigilance analysis of the FDA Adverse Event Reporting System |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 08.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objective: Magnesium oxide is widely used for treating opioid-induced constipation, a serious analgesic-associated problem. Opioid analgesic users are often prescribed non-steroidal anti-inflammatory drugs, which are sometimes combined with acid suppressants to prevent gastrointestinal adverse events. Magnesium preparations combined with acid suppressants may diminish magnesium preparations' laxative effect. This study was aimed at evaluating the effect of magnesium preparations combined with acid suppressants on the incidence of opioid-induced constipation by using the Food and Drug Administration Adverse Event Reporting System. Methods: Adverse events were defined per the Medical Dictionary for Regulatory Activities; the term 'constipation (preferred term code: 10010774)' was used for analysis. After adjusting for patient background factors using propensity score matching, acid suppressants' effect on constipation incidence was evaluated in opioid users prescribed magnesium preparations alone as laxatives by using a test for independence. Key Findings: The Food and Drug Administration Adverse Event Reporting System contains 14,475,614 reports for January 2004 to December 2021. Significantly increased constipation incidence was related to magnesium preparations combined with acid suppressants, especially proton pump inhibitors (P < 0.0001, McNemar's test). Conclusion: Magnesium preparations combined with acid suppressants may diminish magnesium preparations' laxative effect; healthcare professionals should pay attention to this issue | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Laxatives |2 NLM | |
| 650 | 7 | |a Analgesics, Opioid |2 NLM | |
| 650 | 7 | |a Magnesium |2 NLM | |
| 650 | 7 | |a I38ZP9992A |2 NLM | |
| 700 | 1 | |a Inoue, M |e verfasserin |4 aut | |
| 700 | 1 | |a Satake, R |e verfasserin |4 aut | |
| 700 | 1 | |a Wakabayashi, W |e verfasserin |4 aut | |
| 700 | 1 | |a Oura, K |e verfasserin |4 aut | |
| 700 | 1 | |a Goto, F |e verfasserin |4 aut | |
| 700 | 1 | |a Miyasaka, K |e verfasserin |4 aut | |
| 700 | 1 | |a Hirofuji, S |e verfasserin |4 aut | |
| 700 | 1 | |a Iwata, M |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, T |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, H |e verfasserin |4 aut | |
| 700 | 1 | |a Nishida, S |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, S |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, A |e verfasserin |4 aut | |
| 700 | 1 | |a Iguchi, K |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Die Pharmazie |d 1947 |g 78(2023), 11 vom: 04. Dez., Seite 245-250 |w (DE-627)NLM000009180 |x 0031-7144 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2023 |g number:11 |g day:04 |g month:12 |g pages:245-250 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1691/ph.2023.3624 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2023 |e 11 |b 04 |c 12 |h 245-250 | ||